Whom to Biopsy Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators

被引：19
作者：
Loeb, Stacy [1 ,2 ,3 ]
Dani, Hasan [4 ]
机构：
[1] NYU, Dept Urol, New York, NY USA
[2] NYU, Dept Populat Hlth, New York, NY USA
[3] Manhattan Vet Affairs Med Ctr, Dept Urol, New York, NY USA
[4] SUNY, Downstate Coll Med, Dept Urol, Brooklyn, NY USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2017年 / 44卷 / 04期
关键词：
Prostate cancer; Prostate-specific antigen; Biomarkers; Prostate biopsy; Nomograms; PROSTATE HEALTH INDEX; CANCER ANTIGEN 3; MOLECULAR URINE ASSAY; HIGH-GRADE CANCER; RADICAL PROSTATECTOMY; CLINICAL-PERFORMANCE; INTERNAL VALIDATION; EXTERNAL VALIDATION; ACTIVE SURVEILLANCE; KALLIKREIN MARKERS;
D O I：
10.1016/j.ucl.2017.07.001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.
引用
收藏
页码：517 / +
页数：9
相关论文
共 50 条
  • [1] The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy
    Schmid, Marianne
    Hansen, Jens
    Rink, Micheal
    Fisch, Margit
    Chun, Felix
    BIOMARKERS IN MEDICINE, 2013, 7 (06) : 843 - 850
  • [2] Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers
    Watson, Matthew J.
    George, Arvin K.
    Maruf, Mahir
    Frye, Thomas P.
    Muthigi, Akhil
    Kongnyuy, Michael
    Valayil, Subin G.
    Pinto, Peter A.
    FUTURE ONCOLOGY, 2016, 12 (21) : 2417 - 2430
  • [3] Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients
    Iremashvili, Viacheslav
    Barney, Shane L.
    Manoharan, Murugesan
    Kava, Bruce R.
    Parekh, Dipen J.
    Punnen, Sanoj
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (04) : 313 - 317
  • [4] Biomarkers for prostate cancer detection and risk stratification
    Farha, Mark W.
    Salami, Simpa S.
    THERAPEUTIC ADVANCES IN UROLOGY, 2022, 14
  • [5] Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
    Osses, Daniel F.
    Roobol, Monique J.
    Schoots, Ivo G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07):
  • [6] Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy
    Bjurlin, Marc A.
    Taneja, Samir S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 535 - +
  • [7] External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy
    Maximilian Pallauf
    Fabian Steinkohl
    Georg Zimmermann
    Maximilian Horetzky
    Pawel Rajwa
    Benjamin Pradere
    Andrea Katharina Lindner
    Renate Pichler
    Thomas Kunit
    Shahrokh F. Shariat
    Lukas Lusuardi
    Martin Drerup
    World Journal of Urology, 2022, 40 : 2451 - 2457
  • [8] External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy
    Pallauf, Maximilian
    Steinkohl, Fabian
    Zimmermann, Georg
    Horetzky, Maximilian
    Rajwa, Pawel
    Pradere, Benjamin
    Lindner, Andrea Katharina
    Pichler, Renate
    Kunit, Thomas
    Shariat, Shahrokh F.
    Lusuardi, Lukas
    Drerup, Martin
    WORLD JOURNAL OF UROLOGY, 2022, 40 (10) : 2451 - 2457
  • [9] Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer
    Costa-Pinheiro, Pedro
    Patel, Hiten R. H.
    Henrique, Rui
    Jeronimo, Carmen
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1349 - 1358
  • [10] Consideration of comorbidity in risk stratification prior to prostate biopsy
    Liss, Michael A.
    Billimek, John
    Osann, Kathryn
    Cho, Jane
    Moskowitz, Ross
    Kaplan, Adam
    Szabo, Richard J.
    Kaplan, Sherrie H.
    Greenfield, Sheldon
    Dash, Atreya
    CANCER, 2013, 119 (13) : 2413 - 2418
12345